# A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma

> **NCT04194801** · PHASE1,PHASE2 · COMPLETED · sponsor: **CStone Pharmaceuticals** · enrollment: 26 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Phase Ib: Fisogatinib (BLU-554) 400mg in combination with Sugemalimab (CS1001) 1200mg
- **DRUG:** Phase Ib: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg
- **DRUG:** Phase II: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg

## Key facts

- **NCT ID:** NCT04194801
- **Lead sponsor:** CStone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-16
- **Primary completion:** 2021-10-20
- **Final completion:** 2021-10-20
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2023-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04194801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04194801, "A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04194801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*